Clinical Trials Details

S2212 SCARLET (Breast)

Shorter Anthracycline-Free Chemo Immunotherapy Adapted to a Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study

Objective

Key eligibility: TNBC - must not have T4/N+; any N3 or inflammatory BC; no mets; no prior systemic therapy, surgery or radiation.

» Learn more about this trial

Clinical Trial Categories

• Cancers and Other Neoplasms